Medical device industry giant Medtronic (NYSE:MDT) this week offered a 1st look at results from its global Symplicity registry of renal denervation patients, finding that treatment with the company’s Symplicity system appears safe as well as effective in real-world patients.
Renal
St. Jude Medical kicks off renal denervation device study
The 1st patient enrolled today in a St. Jude Medical (NYSE:STJ)-sponsored trial to evaluate the safety and performance of a new renal denervation system in patients with drug-resistant, uncontrolled hypertension, the company said.
Baxter alerts on HomeChoice dialysis machines in Canada, Hong Kong
CryoLife lands FDA win for next-gen HeRO device
The FDA granted 510(k) clearance for CryoLife‘s next-generation HeRO system in treatment of patients undergoing hemodialysis, the company announced.
The new HeRO device includes an adaptor so that it can connect CryoLife’s proprietary venous outflow to other dialysis grafts, including early access grafts, the company reported.
Study: Renal denervation for hypertension may also help stabilize heart rhythms
Renal denervation technologies, which are already the focus of much clinical attention for the potential to treat high blood pressure without drugs, may have a bonus side-effect in keeping the heart in check, according to researchers.
ACC.13 Roundup: A big week for Medtronic’s Symplicity high blood pressure device
Hypertension: ReCor launches post-market study of next-gen Paradise system
California medical device startup ReCor Medical launched a post-market study of its next-generation Paradise renal denervation system in treatment of patients with resistant high blood pressure.
The 50-patient study has already enrolled patients at a participating facility in the Netherlands with the Paradise device, the only renal denervation device on the European market that treats high blood pressure with ultrasound rather than radiofrequency.
St. Jude looks beyond blood pressure for benefits of renal denervation
St. Jude Medical (NYSE:STJ) is aiming to take its renal denervation therapy a step further, looking for signs that the minimally invasive treatment improves health beyond lowering high blood pressure in patients with uncontrolled hypertension.
St. Jude eyes larger patient group in new renal denervation study
Medtech giant St. Jude Medical (NYSE:STJ) launched a new trial of its Enlightn renal denervation system, hoping to demonstrate the value of the technology in a larger clutch of patients.
Hypertension: ReCor Medical lands Euro win for ultrasound-based renal denervation
European regulators granted CE Mark approval to California-based medical device startup ReCor Medical for its 2nd-generation Paradise system, which treats drug-resistant hypertension by targeting the renal nerves.